Because the use of D-IHC tends to result in inferior PD-L1 scores compared to in S-IHC, this could have consequences in terms of therapeutic decisions for tumor samples with scores below the currently established thresholds of “PD-L1 positivity” (established only on the basis of S-IHC to date) according to TPS and/or CPS scores in various cancers. The gene discussed is CD274; the disease is cancer.